Matthew Burchill
Concepts (264)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hepatitis C, Chronic | 4 | 2021 | 153 | 2.110 |
Why?
| Liver | 9 | 2024 | 1839 | 1.170 |
Why?
| Non-alcoholic Fatty Liver Disease | 3 | 2020 | 261 | 1.170 |
Why?
| Dendritic Cells | 8 | 2025 | 478 | 1.050 |
Why?
| Antiviral Agents | 4 | 2021 | 712 | 1.040 |
Why?
| Single-Cell Analysis | 4 | 2021 | 277 | 1.040 |
Why?
| T-Lymphocytes, Regulatory | 8 | 2021 | 375 | 0.990 |
Why?
| CD8-Positive T-Lymphocytes | 6 | 2024 | 857 | 0.980 |
Why?
| Lymphatic Vessels | 3 | 2020 | 61 | 0.960 |
Why?
| T-Lymphocyte Subsets | 3 | 2021 | 412 | 0.850 |
Why?
| Lipoproteins, LDL | 2 | 2020 | 127 | 0.830 |
Why?
| Hepacivirus | 3 | 2021 | 235 | 0.770 |
Why?
| Liver Cirrhosis | 1 | 2024 | 280 | 0.770 |
Why?
| Fatty Liver | 1 | 2024 | 231 | 0.760 |
Why?
| Lymphocyte Activation | 2 | 2015 | 1106 | 0.730 |
Why?
| Endothelial Cells | 4 | 2021 | 749 | 0.670 |
Why?
| Interferons | 1 | 2021 | 194 | 0.660 |
Why?
| Isoquinolines | 2 | 2017 | 41 | 0.630 |
Why?
| Benzazepines | 2 | 2017 | 40 | 0.630 |
Why?
| STAT5 Transcription Factor | 8 | 2008 | 48 | 0.620 |
Why?
| Sulfonamides | 3 | 2020 | 496 | 0.620 |
Why?
| Cell Differentiation | 5 | 2019 | 1902 | 0.590 |
Why?
| Imidazoles | 2 | 2017 | 234 | 0.580 |
Why?
| CD27 Ligand | 2 | 2015 | 9 | 0.580 |
Why?
| Mice | 31 | 2025 | 16937 | 0.540 |
Why?
| Mice, Inbred C57BL | 19 | 2025 | 5440 | 0.530 |
Why?
| Transcriptome | 3 | 2021 | 887 | 0.530 |
Why?
| Indoles | 2 | 2017 | 387 | 0.510 |
Why?
| Tumor Necrosis Factor Receptor Superfamily, Member 7 | 2 | 2015 | 28 | 0.510 |
Why?
| Immunocompromised Host | 1 | 2017 | 198 | 0.510 |
Why?
| T-Lymphocytes | 2 | 2015 | 1928 | 0.490 |
Why?
| Immunity, Innate | 3 | 2020 | 804 | 0.480 |
Why?
| B7-H1 Antigen | 3 | 2025 | 196 | 0.480 |
Why?
| Signal Transduction | 15 | 2025 | 4925 | 0.470 |
Why?
| Receptors, Antigen, T-Cell | 5 | 2024 | 704 | 0.470 |
Why?
| Receptors, Interleukin-2 | 5 | 2007 | 66 | 0.470 |
Why?
| Gene Expression Regulation | 3 | 2021 | 2548 | 0.460 |
Why?
| Animals | 35 | 2025 | 35361 | 0.440 |
Why?
| CD4-Positive T-Lymphocytes | 6 | 2015 | 1056 | 0.420 |
Why?
| Immunologic Memory | 3 | 2016 | 349 | 0.400 |
Why?
| NLR Family, Pyrin Domain-Containing 3 Protein | 2 | 2025 | 149 | 0.390 |
Why?
| Interleukin-2 | 4 | 2008 | 436 | 0.340 |
Why?
| Cell Movement | 4 | 2025 | 945 | 0.340 |
Why?
| Milk Proteins | 3 | 2005 | 33 | 0.330 |
Why?
| Disease Models, Animal | 5 | 2025 | 4063 | 0.320 |
Why?
| Forkhead Transcription Factors | 2 | 2008 | 185 | 0.320 |
Why?
| Homeostasis | 4 | 2016 | 611 | 0.290 |
Why?
| Self Tolerance | 1 | 2008 | 27 | 0.290 |
Why?
| Inflammation | 2 | 2018 | 2736 | 0.280 |
Why?
| Vaccines | 1 | 2012 | 398 | 0.280 |
Why?
| Trans-Activators | 3 | 2005 | 388 | 0.280 |
Why?
| Interleukin-2 Receptor beta Subunit | 1 | 2007 | 18 | 0.270 |
Why?
| Borrelia burgdorferi | 2 | 2004 | 17 | 0.270 |
Why?
| Mice, Transgenic | 9 | 2021 | 2119 | 0.260 |
Why?
| Carbamates | 2 | 2017 | 46 | 0.260 |
Why?
| Pyrrolidines | 2 | 2017 | 67 | 0.260 |
Why?
| Valine | 2 | 2017 | 81 | 0.260 |
Why?
| Mice, Knockout | 12 | 2021 | 2871 | 0.260 |
Why?
| Lyme Disease | 2 | 2004 | 56 | 0.250 |
Why?
| Cytokines | 4 | 2008 | 2017 | 0.250 |
Why?
| B7-1 Antigen | 1 | 2025 | 61 | 0.230 |
Why?
| Interferon Type I | 2 | 2018 | 139 | 0.230 |
Why?
| Interleukin-15 | 4 | 2016 | 82 | 0.220 |
Why?
| Antigen Presentation | 3 | 2021 | 206 | 0.220 |
Why?
| Autoimmunity | 2 | 2024 | 862 | 0.220 |
Why?
| Interleukin-17 | 2 | 2004 | 108 | 0.210 |
Why?
| Bacterial Vaccines | 1 | 2003 | 62 | 0.200 |
Why?
| DNA-Binding Proteins | 3 | 2005 | 1443 | 0.200 |
Why?
| Hematopoietic Stem Cells | 2 | 2024 | 381 | 0.190 |
Why?
| Hepatitis, Alcoholic | 1 | 2021 | 13 | 0.190 |
Why?
| Gene Expression Regulation, Developmental | 1 | 2007 | 821 | 0.190 |
Why?
| Flow Cytometry | 3 | 2019 | 1156 | 0.190 |
Why?
| Lymph Nodes | 2 | 2021 | 472 | 0.180 |
Why?
| NF-kappa B | 1 | 2025 | 653 | 0.180 |
Why?
| Antigens | 2 | 2021 | 355 | 0.180 |
Why?
| Janus Kinase 1 | 1 | 2020 | 24 | 0.180 |
Why?
| Janus Kinase 2 | 1 | 2020 | 32 | 0.180 |
Why?
| Nanoparticles | 1 | 2025 | 374 | 0.180 |
Why?
| Dermis | 1 | 2020 | 31 | 0.170 |
Why?
| Intercellular Junctions | 1 | 2020 | 39 | 0.170 |
Why?
| Azetidines | 1 | 2020 | 40 | 0.170 |
Why?
| Biomarkers | 3 | 2021 | 3973 | 0.170 |
Why?
| Myeloid-Derived Suppressor Cells | 1 | 2021 | 64 | 0.170 |
Why?
| Proteostasis | 1 | 2020 | 27 | 0.170 |
Why?
| Ethanol | 1 | 2025 | 589 | 0.170 |
Why?
| Radiation Tolerance | 1 | 2021 | 100 | 0.170 |
Why?
| Sequence Analysis, RNA | 2 | 2021 | 429 | 0.170 |
Why?
| Permeability | 1 | 2020 | 157 | 0.170 |
Why?
| Humans | 16 | 2025 | 129650 | 0.170 |
Why?
| Epigenesis, Genetic | 1 | 2024 | 613 | 0.170 |
Why?
| Immunity | 1 | 2020 | 139 | 0.160 |
Why?
| STAT3 Transcription Factor | 1 | 2021 | 195 | 0.160 |
Why?
| Male | 9 | 2024 | 63681 | 0.160 |
Why?
| Macrophages | 2 | 2024 | 1480 | 0.160 |
Why?
| Interleukin-1beta | 1 | 2021 | 372 | 0.160 |
Why?
| Cholesterol, Dietary | 1 | 2019 | 18 | 0.160 |
Why?
| Tumor Suppressor Proteins | 2 | 2020 | 317 | 0.160 |
Why?
| Diet, High-Fat | 1 | 2020 | 239 | 0.160 |
Why?
| Kupffer Cells | 1 | 2019 | 49 | 0.150 |
Why?
| Antineoplastic Agents, Immunological | 1 | 2021 | 181 | 0.150 |
Why?
| Endothelium, Lymphatic | 1 | 2018 | 12 | 0.150 |
Why?
| Cell Proliferation | 5 | 2018 | 2391 | 0.140 |
Why?
| Killer Cells, Natural | 2 | 2015 | 427 | 0.140 |
Why?
| Interleukin-6 | 1 | 2021 | 720 | 0.140 |
Why?
| Hypersensitivity | 1 | 2020 | 249 | 0.140 |
Why?
| Homeodomain Proteins | 1 | 2020 | 495 | 0.130 |
Why?
| Immunotherapy | 1 | 2021 | 592 | 0.130 |
Why?
| Hepatocytes | 1 | 2017 | 216 | 0.130 |
Why?
| Bystander Effect | 1 | 2016 | 15 | 0.130 |
Why?
| Drug Resistance, Neoplasm | 1 | 2021 | 759 | 0.130 |
Why?
| Head and Neck Neoplasms | 1 | 2021 | 544 | 0.120 |
Why?
| CD3 Complex | 1 | 2015 | 103 | 0.120 |
Why?
| Receptors, Interleukin-7 | 2 | 2006 | 27 | 0.120 |
Why?
| Proteomics | 1 | 2021 | 1062 | 0.120 |
Why?
| Hepatitis C | 1 | 2017 | 238 | 0.120 |
Why?
| Aging | 1 | 2025 | 1776 | 0.120 |
Why?
| Membrane Glycoproteins | 2 | 2021 | 474 | 0.120 |
Why?
| Coculture Techniques | 1 | 2015 | 226 | 0.120 |
Why?
| Protein Kinase Inhibitors | 1 | 2020 | 891 | 0.110 |
Why?
| Melanoma | 1 | 2021 | 730 | 0.110 |
Why?
| Receptors, Immunologic | 1 | 2015 | 216 | 0.110 |
Why?
| Down Syndrome | 1 | 2020 | 481 | 0.110 |
Why?
| B-Lymphocyte Subsets | 2 | 2005 | 74 | 0.110 |
Why?
| Viral Load | 1 | 2015 | 448 | 0.110 |
Why?
| Antigens, Viral | 1 | 2014 | 178 | 0.110 |
Why?
| Histocompatibility Antigens Class II | 2 | 2013 | 362 | 0.110 |
Why?
| Viral Vaccines | 1 | 2014 | 94 | 0.100 |
Why?
| Alum Compounds | 1 | 2013 | 22 | 0.100 |
Why?
| Chronic Disease | 1 | 2019 | 1720 | 0.100 |
Why?
| Female | 7 | 2025 | 68776 | 0.100 |
Why?
| Melanoma, Experimental | 2 | 2025 | 108 | 0.100 |
Why?
| Drug Therapy, Combination | 1 | 2015 | 1040 | 0.100 |
Why?
| Vaccines, Subunit | 1 | 2012 | 48 | 0.100 |
Why?
| Immunity, Humoral | 1 | 2012 | 118 | 0.090 |
Why?
| Virus Diseases | 1 | 2014 | 211 | 0.090 |
Why?
| Cross-Priming | 1 | 2011 | 18 | 0.090 |
Why?
| Adjuvants, Immunologic | 1 | 2013 | 221 | 0.090 |
Why?
| Toll-Like Receptor 7 | 1 | 2011 | 38 | 0.090 |
Why?
| DNA | 2 | 2021 | 1400 | 0.090 |
Why?
| Immunity, Cellular | 1 | 2012 | 265 | 0.090 |
Why?
| OX40 Ligand | 1 | 2010 | 10 | 0.090 |
Why?
| Aged | 3 | 2019 | 22103 | 0.090 |
Why?
| Interferon-gamma | 2 | 2004 | 770 | 0.090 |
Why?
| Base Sequence | 2 | 2020 | 2142 | 0.080 |
Why?
| Tumor Burden | 2 | 2021 | 286 | 0.080 |
Why?
| Poly I-C | 2 | 2020 | 62 | 0.080 |
Why?
| Prospective Studies | 1 | 2021 | 7133 | 0.080 |
Why?
| Cell Lineage | 2 | 2008 | 333 | 0.080 |
Why?
| Lymphopoiesis | 1 | 2008 | 25 | 0.080 |
Why?
| Middle Aged | 3 | 2019 | 31154 | 0.080 |
Why?
| Sequence Analysis | 1 | 2008 | 37 | 0.070 |
Why?
| CD28 Antigens | 1 | 2008 | 48 | 0.070 |
Why?
| Cell Division | 3 | 2004 | 797 | 0.070 |
Why?
| Pyrazoles | 2 | 2021 | 405 | 0.070 |
Why?
| Aged, 80 and over | 1 | 2019 | 7086 | 0.070 |
Why?
| Interleukins | 1 | 2008 | 241 | 0.070 |
Why?
| Mice, Mutant Strains | 1 | 2007 | 298 | 0.060 |
Why?
| Cell Survival | 4 | 2018 | 1086 | 0.060 |
Why?
| Toll-Like Receptors | 2 | 2020 | 179 | 0.060 |
Why?
| Cells, Cultured | 4 | 2021 | 4083 | 0.060 |
Why?
| Animals, Newborn | 1 | 2008 | 835 | 0.060 |
Why?
| Gene Deletion | 1 | 2007 | 379 | 0.060 |
Why?
| Promoter Regions, Genetic | 2 | 2007 | 1207 | 0.060 |
Why?
| Blotting, Western | 1 | 2008 | 1205 | 0.060 |
Why?
| Lyme Disease Vaccines | 1 | 2004 | 3 | 0.060 |
Why?
| Up-Regulation | 2 | 2005 | 840 | 0.060 |
Why?
| Thymus Gland | 1 | 2005 | 306 | 0.060 |
Why?
| Psoriasis | 1 | 2025 | 87 | 0.060 |
Why?
| Arthritis, Infectious | 1 | 2004 | 60 | 0.050 |
Why?
| Inflammasomes | 1 | 2025 | 126 | 0.050 |
Why?
| Crosses, Genetic | 1 | 2003 | 142 | 0.050 |
Why?
| Cell Line, Tumor | 2 | 2021 | 3215 | 0.050 |
Why?
| Receptors, Interleukin-17 | 1 | 2003 | 5 | 0.050 |
Why?
| Phosphorylation | 3 | 2020 | 1713 | 0.050 |
Why?
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2003 | 100 | 0.050 |
Why?
| Receptors, Interleukin | 1 | 2003 | 43 | 0.050 |
Why?
| Neoplasms | 1 | 2017 | 2470 | 0.050 |
Why?
| Alleles | 1 | 2006 | 845 | 0.050 |
Why?
| Mutation | 2 | 2020 | 3717 | 0.050 |
Why?
| Microglia | 1 | 2025 | 235 | 0.050 |
Why?
| Glycolysis | 1 | 2024 | 311 | 0.050 |
Why?
| Molecular Sequence Data | 1 | 2007 | 2832 | 0.050 |
Why?
| Mice, Inbred BALB C | 2 | 2021 | 1245 | 0.050 |
Why?
| Protein Binding | 2 | 2025 | 2121 | 0.050 |
Why?
| Lupus Erythematosus, Systemic | 1 | 2024 | 247 | 0.050 |
Why?
| Eye Proteins | 1 | 2021 | 88 | 0.050 |
Why?
| Phosphorothioate Oligonucleotides | 1 | 2021 | 11 | 0.050 |
Why?
| Caveolae | 1 | 2021 | 17 | 0.050 |
Why?
| Models, Immunological | 1 | 2021 | 95 | 0.050 |
Why?
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2021 | 26 | 0.050 |
Why?
| Antibodies | 1 | 2003 | 398 | 0.050 |
Why?
| Basic-Leucine Zipper Transcription Factors | 1 | 2021 | 41 | 0.040 |
Why?
| Interleukin-2 Receptor alpha Subunit | 1 | 2021 | 82 | 0.040 |
Why?
| Chemokine CCL21 | 1 | 2020 | 14 | 0.040 |
Why?
| Ovalbumin | 1 | 2021 | 179 | 0.040 |
Why?
| Receptors, CCR7 | 1 | 2020 | 27 | 0.040 |
Why?
| Lymphocyte Depletion | 1 | 2021 | 131 | 0.040 |
Why?
| Nitriles | 1 | 2021 | 172 | 0.040 |
Why?
| Tissue Distribution | 1 | 2021 | 315 | 0.040 |
Why?
| Endocytosis | 1 | 2021 | 163 | 0.040 |
Why?
| Chemotaxis | 1 | 2020 | 129 | 0.040 |
Why?
| GTP-Binding Proteins | 1 | 2020 | 157 | 0.040 |
Why?
| Cell Count | 1 | 2020 | 314 | 0.040 |
Why?
| Polymerization | 1 | 2020 | 124 | 0.040 |
Why?
| Recombinant Proteins | 1 | 2003 | 1304 | 0.040 |
Why?
| Spleen | 2 | 2016 | 507 | 0.040 |
Why?
| Extracellular Signal-Regulated MAP Kinases | 1 | 2020 | 169 | 0.040 |
Why?
| Hippocampus | 1 | 2025 | 874 | 0.040 |
Why?
| Glycoproteins | 1 | 2021 | 338 | 0.040 |
Why?
| Purines | 1 | 2020 | 172 | 0.040 |
Why?
| Interferon-alpha | 1 | 2020 | 194 | 0.040 |
Why?
| Exons | 1 | 2020 | 342 | 0.040 |
Why?
| Adult | 2 | 2019 | 35576 | 0.040 |
Why?
| Protein Domains | 1 | 2020 | 253 | 0.040 |
Why?
| Immune Tolerance | 1 | 2021 | 355 | 0.040 |
Why?
| Hepatitis | 1 | 2019 | 47 | 0.040 |
Why?
| B-Lymphocytes | 1 | 2004 | 815 | 0.040 |
Why?
| Tandem Mass Spectrometry | 1 | 2021 | 524 | 0.040 |
Why?
| Actins | 1 | 2020 | 411 | 0.040 |
Why?
| Vaccination | 2 | 2004 | 1348 | 0.040 |
Why?
| Combined Modality Therapy | 1 | 2021 | 1206 | 0.040 |
Why?
| Pyrimidines | 1 | 2021 | 459 | 0.040 |
Why?
| Antibodies, Monoclonal | 1 | 2004 | 1367 | 0.040 |
Why?
| Repressor Proteins | 1 | 2021 | 406 | 0.040 |
Why?
| Peptide Fragments | 1 | 2021 | 692 | 0.030 |
Why?
| Tumor Microenvironment | 1 | 2021 | 634 | 0.030 |
Why?
| Amino Acids | 1 | 2020 | 485 | 0.030 |
Why?
| Lipid Metabolism | 1 | 2019 | 497 | 0.030 |
Why?
| Primary Cell Culture | 1 | 2016 | 160 | 0.030 |
Why?
| Growth Inhibitors | 2 | 2005 | 44 | 0.030 |
Why?
| Dose-Response Relationship, Immunologic | 1 | 2014 | 82 | 0.030 |
Why?
| RNA, Messenger | 1 | 2021 | 2708 | 0.030 |
Why?
| Autoantigens | 1 | 2016 | 417 | 0.030 |
Why?
| Phenotype | 1 | 2021 | 3076 | 0.020 |
Why?
| Receptors, Interleukin-12 | 1 | 2011 | 7 | 0.020 |
Why?
| Receptor, Interferon alpha-beta | 1 | 2011 | 33 | 0.020 |
Why?
| Disease Progression | 1 | 2019 | 2635 | 0.020 |
Why?
| Mice, Nude | 1 | 2013 | 683 | 0.020 |
Why?
| Cell Communication | 1 | 2013 | 301 | 0.020 |
Why?
| Gene Expression | 1 | 2016 | 1472 | 0.020 |
Why?
| Myeloid Differentiation Factor 88 | 1 | 2011 | 96 | 0.020 |
Why?
| Vaccinia virus | 1 | 2010 | 42 | 0.020 |
Why?
| Time Factors | 1 | 2021 | 6556 | 0.020 |
Why?
| CD40 Antigens | 1 | 2010 | 88 | 0.020 |
Why?
| Listeria monocytogenes | 1 | 2010 | 123 | 0.020 |
Why?
| Interleukin-7 | 1 | 2008 | 59 | 0.020 |
Why?
| Immunization | 1 | 2010 | 411 | 0.020 |
Why?
| Receptors, Interleukin-15 | 1 | 2006 | 3 | 0.020 |
Why?
| Resting Phase, Cell Cycle | 1 | 2006 | 15 | 0.020 |
Why?
| Transcription Factors | 2 | 2005 | 1651 | 0.020 |
Why?
| Adoptive Transfer | 1 | 2006 | 218 | 0.020 |
Why?
| PAX5 Transcription Factor | 1 | 2005 | 14 | 0.020 |
Why?
| bcl-X Protein | 1 | 2005 | 42 | 0.020 |
Why?
| Bone Marrow | 1 | 2006 | 271 | 0.010 |
Why?
| Proto-Oncogene Proteins c-raf | 1 | 2004 | 45 | 0.010 |
Why?
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2005 | 232 | 0.010 |
Why?
| Protein Tyrosine Phosphatases | 1 | 2004 | 168 | 0.010 |
Why?
| PTEN Phosphohydrolase | 1 | 2004 | 161 | 0.010 |
Why?
| Phosphatidylinositol 3-Kinases | 1 | 2004 | 359 | 0.010 |
Why?
| Oligonucleotide Array Sequence Analysis | 1 | 2004 | 769 | 0.010 |
Why?
| Proto-Oncogene Proteins c-akt | 1 | 2004 | 431 | 0.010 |
Why?
| Down-Regulation | 1 | 2004 | 636 | 0.010 |
Why?
| Stem Cells | 1 | 2005 | 577 | 0.010 |
Why?
| Proto-Oncogene Proteins | 1 | 2004 | 638 | 0.010 |
Why?
|
|
Burchill's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|